DBV DBV Technologies SA

Combined General Meeting of June 11, 2025

Combined General Meeting of June 11, 2025

Châtillon, France, May 15, 2025

Combined General Meeting of June 11, 2025

Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on June 11, 2025, at 02:00 p.m. CEST (08:00 a.m EST) at the Company’s headquarters located at IRO Building, 107 Avenue de la République, 92320 Châtillon, France.

The preliminary notice (avis de réunion) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this General Meeting was published in the French “Bulletin des Annonces Légales Obligatoires (BALO)” dated May 07, 2025 (No. 2501507). The meeting notice (avis de convocation) will be published in the BALO and in the legal newspaper Affiches parisiennes on May 21, 2025.

The information and preparatory documents for this General Meeting are available to the Company's shareholders in accordance with the procedures and within the time limits provided for by the applicable legal and regulatory provisions. The documents referred to in Article R.22-10-23 of the French Commercial Code are available on the Company's website ().

Any shareholder wishing to receive these documents by post or electronically may make a request until midnight, Paris time, on June 06, 2025 (i.e., the fifth day before the General Meeting) by contacting the Company at . For bearer shareholders, this request must be accompanied by a certificate of registration in the securities accounts held by an intermediary, in accordance with Article L. 211-3 of the French Monetary and Financial Code.

Webcast of the Annual General Meeting

A live webcast of the General Meeting will be available on the Company's website at the following address:

The recorded webcast of the General Meeting will be disclosed no later than seven (7) business days after the date of the General Meeting and will remain accessible on the Company’s website for at least the minimum legal and regulatory period from its publication online.

About DBV Technologies

DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).

For more information, please visit and engage with us on and .

Investor Contact

Katie Matthews

DBV Technologies

Media Contact

Angela Marcucci

DBV Technologies

Attachment



EN
15/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE

DBV Technologies Announces First Subject Screened in COMFORT Toddlers ...

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been act...

 PRESS RELEASE

DBV Technologies annonce le screening du premier sujet de l'étude comp...

DBV Technologies annonce le screening du premier sujet de l'étude complémentaire d’innocuité COMFORT Toddlers chez les enfants âgés de 1 à 3 ans allergiques à l’arachide. Châtillon, France, le 25 juin (22 :30 CEST) 2025 DBV Technologies annonce le screening du premier sujet de l'étude complémentaire d’innocuité COMFORT Toddlers chez les enfants âgés de 1 à 3 ans allergiques à l’arachide. Screening du premier sujet à l'Institut de recherche en médecine respiratoire du Michigan, sous la direction du Dr Jeffrey Leflein, investigateur principal.D'autres sites ont été activés et prévoient des...

 PRESS RELEASE

DBV Technologies to Participate in Upcoming EAACI Congress 2025

DBV Technologies to Participate in Upcoming EAACI Congress 2025 Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presen...

 PRESS RELEASE

DBV Technologies participera au prochain congrès EAACI 2025

DBV Technologies participera au prochain congrès EAACI 2025 Châtillon, France, le 12 juin (22:30 CEST) 2025 DBV Technologies participera au prochain congrès EAACI 2025 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT ; CUSIP : 23306J309), une société biopharmaceutique en phase clinique, annonce aujourd'hui sa participation au congrès European Academy of Allergy and Clinical Immunology (EAACI) qui se tiendra du 13 au 16 juin 2025 à Glasgow, au Royaume-Uni. DBV présentera deux posters, organisera un symposium et tiendra un stand dans le hall d'exposition d...

 PRESS RELEASE

DBV Technologies Announces the Voting Results of its 2025 Combined Gen...

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch